Author:
Uyterlinde W. I.,Mallo H. A.,Haanen J. B. A. G.
Reference19 articles.
1. Baas, J. M., Krens, L. L., Guchelaar, H-J., Ouwerkerk, J., De Jong F. A., & Lavrijsen, A. P. M. (2012). Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treatment Reviews, 38, 505–514.
2. Barber, N. A., & Ganti, A. K. (2011). Pulmonary toxicities from targeted therapy: A review. Targeted Oncology, 6, 235–243.
3. Boers-Doets, C., Ouwerkerk, J., Schrama, N., & Gallmont, A. (2010). Huid-, haar-, nagel- en oogreacties bij targeted therapie, Oncologica, 2, 21–24.
4. Costa, A., Tejpar, S., Prenen, H., & Van Cutsem, E. (2011). Hypomagnesaemia and targeted-epidermal growth factor receptor (EGFR) agents. Targeted Oncology, 6, 227–233.
5. Van Erp N. P., Gelderblom, H., & Guchelaar, H. J. (2009). Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews, 8, 692–706.